Abnormal kidney function test and clinical outcomes
At admission to hospital, majority of recovered and died patients
(97.99%) had normal kidney (stage I) (n= 338, 85.14%) and mild (stage
II) AKI (n=51, 12.85%) (Table 2). The baseline S.Cr and consequently,
eGFR was not significantly varied between died and recovered patient
(Mean ± SD, 0.91 ± 0.09 versus 0.86 ± 0.28; t-test ,
p=0.184), (Mean ± SD, 126.17 ± 30.51 versus 139.39 ±
54.19, t-test , p=0.106) respectively. BUN for recovered and died
patients at admission was not significantly differed (Mean
± SD, 20.19 ± 9.74 versus 21.22 ± 7.60; p=0.459) (Table 3, Fig.
1).
For died patients, the day before death shows 24 (52.17%) patients had
progressed to stage III and IV AKI (Table 2). Comparing to the recovered
patients, S.Cr and BUN were significantly higher one day before death
(Mean ± SD, 2.07 ± 1.49 versus 0.86 ± 0.28; p=0.000) and
(Mean ± SD, 34.43 ± 12.19 versus 20.19 ± 9.74; p=0.000)
respectively. The estimated GFR was lower for patients the day before
death comparing to those who have been recovered from COVID-19 (Mean
± SD, 67.99 ± 42.26 versus 139.39 ± 54.19; p=0.000) (Table 3,
Fig. 1).
Of 46 died patients; all of the kidney function tests were abnormally
changed from baseline to the day before death. The mean of S.Cr was
increased by more than 47% from the baseline (Mean ± SD, 0.98 ±
0.10 versus 2.07 ± 1.49; p=0.000). Consequently, the estimated GFR
decreased from baseline by more than 63% (Mean ± SD, 109.12 ±
24.69 versus 67.99 ± 42.26; p=0.000). Similarly, BUN was increased more
than 61% from the baseline value (Mean ± SD, 109.12 ± 24.69
versus 67.99 ± 42.26; p=0.000) (Table 3, Fig. 1).